This study investigates the use of gene-edited tumor infiltrating lymphocyte (TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are a type of cell therapy where cells are taken from a tumor, modified, and then given back to the patient.
The study evaluates the safety and effectiveness of this therapy. Researchers are looking at how well patients tolerate the treatment and its impact on their condition.
- Who can participate: Participants must be between 18 and 70 years old with pancreatic ductal adenocarcinoma and have completed tumor resection for TIL production.
- Study details: Participants will receive gene-edited TIL therapy.
How understandable was the trial content above?
Hard to understand
Easy to understand